glp-1 side effect law firm in michigan semaglutide office Lawsuits: What to Know as a Prescriber At least 3,000 patients have

The new label includes references to some of those postmarketing risks, including intestinal obstruction, [and] severe constipation including fecal impaction. Some patients who took Zepbound have filed lawsuits, accusing Eli Lilly of failing to properly warn them that Zepbound could increase their risk of severe gut problems, including bowel obstructions, pancreatitis, and gastroparesis

doi: 10.3390/brainsci13111503 [DOI] [PMC free article] [PubMed] [Google Scholar] 33

[4] It is important to distinguish pancreatitis from the common gastrointestinal side effects that affect many semaglutide users, particularly during dose escalation

Strategic partnerships and supply chain resilience will be essential

Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at least comparable benefit to dulaglutide, an older GLP-1 receptor agonist with established cardiovascular efficacy